Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 16Triple Negative Breast Neoplasms 1Rectal Neoplasms 1Malignant Solid Neoplasm 1Inflammatory Breast Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms, Male 1Bladder Urothelial Carcinoma 1Advanced Breast Carcinoma 1Adenocarcinoma Of Esophagus 1

Interventions

Cyclophosphamide 13Doxorubicin 9Trastuzumab 8Taxes 7Paclitaxel 7Docetaxel 5Carboplatin 5Albumin-Bound Paclitaxel 5Radiotherapy 4Epirubicin 4pertuzumab 3pembrolizumab 3Melphalan 3130-nm albumin-bound paclitaxel 3eribulin 2Thiotepa 2Tamoxifen 2Peripheral Blood Stem Cell Transplantation 2Lapatinib 2Fluorouracil 2Filgrastim 2Bevacizumab 22C4 antibody 2trastuzumab biosimilar HLX02 1talimogene laherparepvec 1sargramostim 1ruxolitinib 1romidepsin 1pegfilgrastim 1pazopanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Inflammatory Breast Neoplasms × PF-05280014 × Clear all
NCT03101748 2026-02-12

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

M.D. Anderson Cancer Center

Phase 1/2 Terminated
34 enrolled 15 charts
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡